Ibrutinib uses more than 400 million in China

In 2018, Ibrutinib's global performance reached $6.21 billion.

Ibrutinib is a daily, easy-to-use oral dosage form and the world's first Bruton tyrosine kinase (BTK) inhibitor. Bruton tyrosine kinase is a key signaling molecule in B cell receptor signaling pathway, which plays an important role in the survival and proliferation of malignant B cells (cancer cells). Yike can inhibit the signal of proliferation and proliferation of malignant B cells.

Ibrutinib was developed by Cilag GmbH International (subsidiary of Jansen Pharmaceutical Company) and harmacyclics LLC (Alberville Company). Xi'an Yangsen Pharmaceutical Co., Ltd. is responsible for the marketing of Yike in mainland China, Pharmacyclics LLC and Janssen Biotech Inc. are responsible for the marketing of Ibrutinib in the United States, and other countries and regions are responsible for the marketing of Yangsen Company.

Ibrutinib has been approved in 93 countries and is widely used in more than 135,000 patients worldwide. In addition to the indications of Fahrenheit's macroglobulinemia, Yike can be used alone in patients with mantle cell lymphoma and chronic lymphoblastic leukemia/small lymphocyte lymphoma who have received at least one treatment in the past.